Researchers at Tufts University, led by Krishna Kumar, are developing an innovative weight loss drug that incorporates a novel four-hormone mechanism. This approach aims to surpass the effectiveness of current treatments like Ozempic and Mounjaro by targeting an additional appetite-suppressing gut hormone. Their goal is to achieve substantial weight loss akin to bariatric surgery, while avoiding its invasive nature and side effects, such as muscle loss and nausea. The compound seeks to address obesity's associated health risks, which impact over 650 million individuals globally.
"Obesity is linked to over 180 different disease conditions, including cancer, cardiovascular disease, osteoarthritis, liver disease, and type 2 diabetes, and affects over 650 million people worldwide."
"While weight loss drugs currently on the market and in development target one, two, or even three hormone receptors related to glucose metabolism and the desire to eat, the Tufts team has identified a fourth target that could potentially further enhance the control strategy."
Collection
[
|
...
]